Lymphoma Clinical Trials in Taiyuan, Shanxi
18 recruitingTaiyuan, Shanxi, China
Showing 1–18 of 18 trials
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled195 locationsNCT06136559
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled246 locationsNCT06717347
Recruiting
Phase 2
A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)
Primary Central Nervous System LymphomaPCNSL
Tongji Hospital110 enrolled3 locationsNCT07350850
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 1Phase 2
Evaluate the Safety and Clinical Activity of HH2853
Advanced Solid TumorPeripheral T Cell LymphomaFL Lymphoma+1 more
Haihe Biopharma Co., Ltd.254 enrolled25 locationsNCT04390737
Recruiting
Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines150 enrolled64 locationsNCT06970743
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 3
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Peripheral T Cell Lymphoma
Dizal Pharmaceuticals218 enrolled50 locationsNCT07234162
Recruiting
Phase 1
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
Non-Hodgkin Lymphoma
Hangzhou GluBio Pharmaceutical Co., Ltd.110 enrolled13 locationsNCT06219356
Recruiting
Phase 1Phase 2
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.97 enrolled21 locationsNCT07124936
Recruiting
Phase 1
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Advanced Solid TumorAdvanced Lymphoma
CStone Pharmaceuticals480 enrolled38 locationsNCT05279300
Recruiting
Not Applicable
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Acute Lymphoblastic LeukemiaMultiple MyelomaLymphoma
Hebei Senlang Biotechnology Inc., Ltd.50 enrolled1 locationNCT05618041
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Diffuse Large Cell B-lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.55 enrolled24 locationsNCT06854445
Recruiting
Not Applicable
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
Lymphoma, Non-HodgkinAcute Lymphocytic LeukemiaRelapsed/Refractory Multiple Myeloma
Shanxi Bethune Hospital45 enrolled1 locationNCT06783816
Recruiting
Phase 2
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.80 enrolled30 locationsNCT06566586